Jeon Hong Bae, Yoon Jae Hee, Lim Nam Kyu
Department of Plastic and Reconstructive Surgery, Dankook University Hospital, Cheonan, Chungnam, Republic of Korea.
Department of Plastic and Reconstructive Surgery, Dankook University College of Medicine, Cheonan, Chungnam, Republic of Korea.
Arch Plast Surg. 2022 May 27;49(3):310-314. doi: 10.1055/s-0042-1748643. eCollection 2022 May.
The emergence of vaccines for coronavirus disease 2019 (COVID-19) raises risk of possible adverse events from interaction between the vaccines and facial aesthetic care. A 47-year-old female with no medical comorbidities visited our emergency room due to midface painful swelling after 3 hours following receiving the second dose of the messenger RNA BNT162b2 COVID-19 vaccine. About 14 years ago, she underwent nonsurgical augmentation on the nasojugal groove with a calcium hydroxylapatite dermal filler. We performed incision and drainage under general anesthesia on the next day. During operation, yellowish pus-like materials bulged out. After an operation, we performed a combination therapy with antibiotics and methylprednisolone. Her symptoms improved day by day after surgery, and then a complete recovery was achieved at 3 weeks after the treatment. In conclusion, providers of aesthetic procedures are to be aware of the potential risks of such vaccines for patients who already had or seek to receive dermal filler injections.
2019冠状病毒病(COVID-19)疫苗的出现增加了疫苗与面部美容护理相互作用导致不良事件的风险。一名47岁无基础疾病的女性在接种第二剂信使核糖核酸BNT162b2 COVID-19疫苗3小时后,因面部中部疼痛肿胀前来我院急诊室就诊。约14年前,她曾使用羟基磷灰石真皮填充剂对鼻泪沟进行非手术填充。次日,我们在全身麻醉下进行了切开引流。术中,有淡黄色脓性物质流出。术后,我们采用抗生素和甲泼尼龙联合治疗。术后她的症状逐日改善,治疗3周后完全康复。总之,美容手术提供者应意识到此类疫苗对已接受或寻求接受真皮填充剂注射的患者的潜在风险。